Patents by Inventor David Maillard

David Maillard has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NOVEL CRYSTALLINE FORMS OF 1-(4-{[6-AMINO-5-(4-PHENOXY-PHENYL)-PYRIMIDIN-4-YLAMINO]-METHYL}-4-FLUORO-PIPERIDIN-1-YL)-PROPENONE, SALT FORMS THEREOF, AND PROCESSES TO OBTAIN
    Publication number: 20240132472
    Abstract: A solid form of 1-(4-{[6-Amino-5-(4-phenoxy-phenyl)-pyrimidin-4-ylamino]-methyl}-4-fluoro-piperidin-1-yl)-propenone, or pharmaceutically acceptable salts thereof, is useful as a BTK inhibitor.
    Type: Application
    Filed: December 7, 2023
    Publication date: April 25, 2024
    Applicant: Merck Patent GmbH
    Inventors: Michael LANGE, Clemens Kuetin, Tobias Schiueter, Werner Mederski, David Maillard, Edoardo Burini
  • Crystalline forms of 1-(4-{[6-amino-5-(4-phenoxy-phenyl)-pyrimidin-4-ylamino]-methyl}-4-fluoro-piperidin-1-yl)-propenone, salt forms thereof, and processes to obtain
    Patent number: 11878967
    Abstract: A solid form of 1-(4-{[6-Amino-5-(4-phenoxy-phenyl)-pyrimidin-4-ylamino]-methy}-4-fluoro-piperidin-1-yl)-propenone, or pharmaceutically acceptable salts thereof, is useful as a BTK inhibitor.
    Type: Grant
    Filed: June 17, 2019
    Date of Patent: January 23, 2024
    Assignee: Merck Patent GmbH
    Inventors: Michael Lange, Clemens Kuehn, Tobias Schlueter, Werner Mederski, David Maillard, Edoardo Burini
  • Process for the preparation of metformin
    Patent number: 11465964
    Abstract: The present invention relates to an improved process for the preparation of metformin hydrochloride, an important drug in the first line treatment of Type II Diabetes.
    Type: Grant
    Filed: February 5, 2019
    Date of Patent: October 11, 2022
    Assignee: Merck Patent GmbH
    Inventors: Camille Correia, Renaud Poli, Serge Gerbaut, Marc Dittmann, David Maillard, Sebastian Haertner
  • Crystalline form of (S)-[2-chloro-4-fluoro-5-(7-morpholin-4-yl-quinazolin-4-yl)phenyl]-(6-methoxy-pyridazin-3-yl)-methanol
    Patent number: 11103512
    Abstract: A crystalline form of (S)-[2-chloro-4-fluoro-5-(7-morpholin-4-yl-quinazolin-4-yl)-phenyl]-(6-methoxy-pyridazin-3-yl)-methanol can be prepared as a pharmaceutical composition.
    Type: Grant
    Filed: March 28, 2018
    Date of Patent: August 31, 2021
    Assignee: Merck Patent GmbH
    Inventors: Michael Lange, Clemens Kuehn, Thomas Fuchss, David Maillard, Marcel Breuning, Marco Poma, Edoardo Burini
  • NOVEL CRYSTALLINE FORMS OF 1-(4-{[6-AMINO-5-(4-PHENOXY-PHENYL)-PYRIMIDIN-4-YLAMINO]-METHYL}-4-FLUORO-PIPERIDIN-1-YL)-PROPENONE, SALT FORMS THEREOF, AND PROCESSES TO OBTAIN
    Publication number: 20210261525
    Abstract: A solid form of 1-(4-{[6-Amino-5-(4-phenoxy-phenyl)-pyrimidin-4-ylamino]-methy}-4-fluoro-piperidin-1-yl)-propenone, or pharmaceutically acceptable salts thereof, is useful as a BTK inhibitor.
    Type: Application
    Filed: June 17, 2019
    Publication date: August 26, 2021
    Applicant: Merck Patent GmbH
    Inventors: Michael LANGE, Clemens Kuehn, Tobias Schlueter, Werner Mederski, David Maillard, Edoardo Burini
  • Crystalline form of (S)-[2-chloro-4-fluoro-5-(7-morpholin-4-yl-quinazolin-4-yl)phenyl]-(6-methoxy-pyridazin-3-yl)-methanol
    Patent number: 11065255
    Abstract: A crystalline form of (S)-[2-chloro-4-fluoro-5-(7-morpholin-4-yl-quinazolin-4-yl)-phenyl]-(6-methoxy-pyridazin-3-yl)-methanol can be prepared as a pharmaceutical composition.
    Type: Grant
    Filed: March 28, 2018
    Date of Patent: July 20, 2021
    Assignee: Merck Patent GmbH
    Inventors: Michael Lange, Clemens Kuehn, Thomas Fuchss, David Maillard, Marcel Breuning, Marco Poma, Edoardo Burini
  • Solid form of (S)-[2-chloro-4-fluoro-5-(7-morpholin-4-yl-quinazolin-4-yl)phenyl]-(6-methoxy-pyridazin-3-yl)-methanol
    Patent number: 11053233
    Abstract: An anhydrous disordered crystalline (S)-[2-chloro-4-fluoro-5-(7-morpholin-4-yl-quinazolin-4-yl)-phenyl]-(6-methoxy-pyridazin-3-yl)-methanol can be used in pharmaceutical compositions.
    Type: Grant
    Filed: March 28, 2018
    Date of Patent: July 6, 2021
    Assignee: Merck Patent GmbH
    Inventors: Michael Lange, Clemens Kuehn, Thomas Fuchss, David Maillard, Marcel Breuníng, Marco Poma, Edoardo Burini
  • Crystalline form of (S)-[2-chloro-4-fluoro-5-(7-morpholin-4-yl-quinazolin-4-yl)phenyl]-(6-methoxy-pyridazin-3-yl)-methanol
    Publication number: 20210113572
    Abstract: A crystalline form of (S)-[2-chloro-4-fluoro-5-(7-morpholin-4-yl-quinazolin-4-yl)-phenyl]-(6-methoxy-pyridazin-3-yl)-methanol can be prepared as a pharmaceutical composition.
    Type: Application
    Filed: March 28, 2018
    Publication date: April 22, 2021
    Applicant: Merck Patent GmbH
    Inventors: Michael LANGE, Clemens Kuehn, Thomas Fuchss, David Maillard, Marcel Breuning, Marco Poma, Edoardo Burini
  • PROCESS FOR THE PREPARATION OF METFORMIN
    Publication number: 20210040035
    Abstract: The present invention relates to an improved process for the preparation of metformin hydrochloride, an important drug in the first line treatment of Type II Diabetes.
    Type: Application
    Filed: February 5, 2019
    Publication date: February 11, 2021
    Applicant: Merck Patent GmbH
    Inventors: Camille CORREIA, Renaud POLI, Serge GERBAUT, Marc DITTMANN, David MAILLARD, Sebastian HAERTNER
  • Solid form of (S)-[2-chloro-4-fluoro-5-(7-morpholin-4-yl-quinazolin-4-yl)phenyl]-(6-methoxy-pyridazin-3-yl)-methanol
    Publication number: 20200123144
    Abstract: An anhydrous disordered crystalline (S)-[2-chloro-4-fluoro-5-(7-morpholin-4-yl-quinazolin-4-yl)-phenyl]-(6-methoxy-pyridazin-3-yl)-methanol can be used in pharmaceutical compositions.
    Type: Application
    Filed: March 28, 2018
    Publication date: April 23, 2020
    Applicant: Merck Patent GmbH
    Inventors: Michael Lange, Clemens Kuehn, Thomas Fuchss, David Maillard, Marcel Breuning, Marco Poma, Edoardo Burini
  • Method for the production of praziquantel and precursors thereof
    Patent number: 10273213
    Abstract: The present invention provides methods of preparing Praziquantel, in particular (R)-Praziquantel and analogues thereof in a stereoselective manner. One method involves asymmetric hydrogenation of the following intermediate compound and subsequent cyclization.
    Type: Grant
    Filed: August 10, 2016
    Date of Patent: April 30, 2019
    Assignee: Merck Patent GmbH
    Inventors: Luc Eberhardt, Andreas Waechtler, David Maillard, Stefan Lehmann
  • Method for the production of praziquantel
    Patent number: 10160758
    Abstract: The present invention relates to a method for the racemization of enantiomerically pure or enantiomerically enriched Praziquantel under basic conditions and a method for the production of (R)-Praziquantel in enantiopure or enantiomerically enriched form, which comprises the racemization method.
    Type: Grant
    Filed: November 17, 2015
    Date of Patent: December 25, 2018
    Assignee: MERCK PATENT GMBH
    Inventors: Andreas Waechtler, Hadia Saleh-Kassim, Christian Jasper, Joern Kolb, David Maillard
  • Method and apparatus for monitoring fluid reductant for internal combustion engine exhaust
    Patent number: 10145285
    Abstract: A method and means of determining the quality of a fluid reductant used in selective catalytic reduction to reduce NOx emissions from an internal combustion engine. Short and long term average of NOx conversion efficiency are compared with thresholds, in order to determine if failure of selective catalytic reduction is due to incorrect reductant, or to failure of the catalyst device.
    Type: Grant
    Filed: June 26, 2014
    Date of Patent: December 4, 2018
    Assignee: Jaguar Land Rover Limited
    Inventor: David Maillard
  • METHOD FOR THE PRODUCTION OF PRAZIQUANTEL AND PRECURSORS THEREOF
    Publication number: 20180251428
    Abstract: The present invention provides methods of preparing Praziquantel, in particular (R)-Praziquantel and analogues thereof in a stereoselective manner. One method involves asymmetric hydrogenation of the following intermediate compound and subsequent cyclization.
    Type: Application
    Filed: August 10, 2016
    Publication date: September 6, 2018
    Applicant: Merck Patent GmbH
    Inventors: Luc EBERHARDT, Andreas WAECHTLER, David MAILLARD, Stefan LEHMANN
  • METHOD FOR THE PRODUCTION OF PRAZIQUANTEL
    Publication number: 20180155339
    Abstract: The present invention relates to a method for the racemization of enantiomerically pure or enantiomerically enriched Praziquantel under basic conditions and a method for the production of (R)-Praziquantel in enantiopure or enantiomerically enriched form, which comprises the racemization method.
    Type: Application
    Filed: November 17, 2015
    Publication date: June 7, 2018
    Applicant: MERCK PATENT GMBH
    Inventors: Andreas WAECHTLER, Hadia SALEH-KASSIM, Christian JASPER, Joern KOLB, David MAILLARD
  • Method for the production of Praziquantel and precursors thereof
    Patent number: 9932337
    Abstract: The present invention relates to methods for the production of enantiopure or enantioenriched Praziquantel precursors and to methods for the production of enantiopure or enantioenriched Praziquantel comprising the methods for the production of the Praziquantel precursors. The present invention further relates to compounds or intermediates useful in such methods.
    Type: Grant
    Filed: November 19, 2015
    Date of Patent: April 3, 2018
    Assignee: Merck Patent GmbH
    Inventors: David Maillard, Andreas Waechtler, Jeremy Maurin, Ewgenij Wakaresko, Christian Jasper
  • Method For The Production of Praziquantel and Precursors Thereof
    Publication number: 20170320873
    Abstract: The present invention relates to methods for the production of enantiopure or enantioenriched Praziquantel precursors and to methods for the production of enantiopure or enantioenriched Praziquantel comprising the methods for the production of the Praziquantel precursors. The present invention further relates to compounds or intermediates useful in such methods.
    Type: Application
    Filed: November 19, 2015
    Publication date: November 9, 2017
    Applicant: Merck Patent GmbH
    Inventors: David MAILLARD, Andreas WAECHTLER, Jeremy MAURIN, Ewgenij WAKARESKO, Christian JASPER
  • METHOD AND APPARATUS FOR MONITORING FLUID REDUCTANT FOR INTERNAL COMBUSTION ENGINE EXHAUST
    Publication number: 20160146080
    Abstract: A method and means of determining the quality of a fluid reductant used in selective catalytic reduction to reduce NOx emissions from an internal combustion engine. Short and long term average of NOx conversion efficiency are compared with thresholds, in order to determine if failure of selective catalytic reduction is due to incorrect reductant, or to failure of the catalyst device.
    Type: Application
    Filed: June 26, 2014
    Publication date: May 26, 2016
    Inventor: David Maillard
  • Process of isolating enantiomer components from enantiomer mixtures by particle-size-controlled crystallization
    Patent number: 8846911
    Abstract: The present invention discloses a process for isolating enantiomer components from a mixture of enantiomers through particle-size-controlled crystallization, comprising the steps of: (a) forming a solution of a mixture of enantiomers (R) and (S) in a solvent in the absence of any further additives or agents; (b) seeding the solution of step (a) simultaneously or consecutively with seed crystals of enantiomer (R) and with seed crystals of enantiomer (S), wherein the seed crystals of enantiomer (R) differ in size and/or in quantity from the seed crystals of enantiomer (S) to allow separation of the crystals composed of a mixture enriched with enantiomer (R) from the crystals composed of a mixture enriched with enantiomer (S); (c) inducing simultaneous crystallization of enantiomer (R) and enantiomer (S); and (d) isolating crystals composed of a mixture enriched with enantiomer (R) from crystals composed of a mixture enriched with enantiomer (S) through size separation of the crystals, preferably through sieving
    Type: Grant
    Filed: August 26, 2013
    Date of Patent: September 30, 2014
    Assignee: Poxel
    Inventors: David Maillard, Guntram Koller, Ewgenij Wakaresko, Sabine Gottburg-Reininger
  • PROCESS OF ISOLATING ENANTIOMER COMPONENTS FROM ENANTIOMER MIXTURES BY PARTICLE-SIZE-CONTROLLED CRYSTALLIZATION
    Publication number: 20130345421
    Abstract: The present invention discloses a process for isolating enantiomer components from a mixture of enantiomers through particle-size-controlled crystallization, comprising the steps of: (a) forming a solution of a mixture of enantiomers (R) and (S) in a solvent in the absence of any further additives or agents; (b) seeding the solution of step (a) simultaneously or consecutively with seed crystals of enantiomer (R) and with seed crystals of enantiomer (S), wherein the seed crystals of enantiomer (R) differ in size and/or in quantity from the seed crystals of enantiomer (S) to allow separation of the crystals composed of a mixture enriched with enantiomer (R) from the crystals composed of a mixture enriched with enantiomer (S); (c) inducing simultaneous crystallization of enantiomer (R) and enantiomer (S); and (d) isolating crystals composed of a mixture enriched with enantiomer (R) from crystals composed of a mixture enriched with enantiomer (S) through size separation of the crystals, preferably through sieving
    Type: Application
    Filed: August 26, 2013
    Publication date: December 26, 2013
    Inventors: David MAILLARD, Guntram KOLLER, Ewgenij WAKARESKO, Sabine GOTTBURG-REININGER